908 Devices (MASS) Expected to Release Earnings on Tuesday

Key Points

• 908 Devices is expected to report Q3 2026 results before the market opens on Tuesday, November 10. Analysts forecast a loss of $0.16 per share and revenue of $18.31 million; the earnings call is scheduled for 8:30 a.m. ET.
• The company beat expectations in its latest quarter, reporting a $0.11 per-share loss versus the projected $0.14 loss and revenue of $16.07 million versus estimates of $15.37 million. However, it remains unprofitable, with a negative net margin of 56.96%.
• Shares recently traded at $10.82, up 5.9%. Analysts give the stock a “Moderate Buy” consensus rating with an average price target of $12.83, while insiders have sold 141,915 shares worth approximately $1.48 million over the past 90 days.

908 Devices (NASDAQ:MASS - Get Free Report) is projected to announce its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect 908 Devices to post earnings of ($0.16) per share and revenue of $18.31 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

908 Devices (NASDAQ:MASS - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. 908 Devices had a negative net margin of 56.96% and a negative return on equity of 12.54%. The business had revenue of $16.07 million during the quarter, compared to analysts' expectations of $15.37 million. On average, analysts expect 908 Devices to post ($0.59) EPS for the current fiscal year and ($0.40) EPS for the next fiscal year.

908 Devices Trading Up 5.9%

MASS traded up $0.61 on Tuesday, hitting $10.82. 51,776 shares of the stock traded hands, compared to its average volume of 336,429. The business has a fifty day moving average price of $11.21 and a two-hundred day moving average price of $8.38. The firm has a market capitalization of $447.11 million, a PE ratio of -11.39 and a beta of 0.63. 908 Devices has a 52 week low of $5.03 and a 52 week high of $13.35.

Analyst Upgrades and Downgrades

MASS has been the topic of a number of research reports. Canaccord Genuity Group initiated coverage on 908 Devices in a research report on Thursday, September 10th. They set a "buy" rating and a $13.50 price objective on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 908 Devices in a research report on Friday, August 7th. Wall Street Zen cut 908 Devices from a "buy" rating to a "hold" rating in a research report on Saturday, September 12th. Roth Capital lifted their price target on shares of 908 Devices from $11.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Finally, Stifel Nicolaus boosted their price target on shares of 908 Devices from $10.00 to $12.00 and gave the company a "buy" rating in a report on Wednesday, August 12th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $12.83.

Insider Activity

In other 908 Devices news, SVP John Kenneweg sold 5,257 shares of the company's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $10.22, for a total value of $53,726.54. Following the sale, the senior vice president directly owned 57,784 shares in the company, valued at $590,552.48. This represents a 8.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Brown sold 30,000 shares of the company's stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $11.89, for a total value of $356,700.00. Following the completion of the sale, the director owned 745,559 shares in the company, valued at $8,864,696.51. This trade represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 141,915 shares of company stock worth $1,477,002. Company insiders own 28.20% of the company's stock.

908 Devices Company Profile

908 Devices Inc is a Boston-based analytical technology company that develops purpose-built mass spectrometers for use outside traditional laboratory environments. Its instruments are designed to provide rapid chemical and biological analysis in the field, helping users identify unknown substances and make time-sensitive decisions.

The company's product portfolio includes the MX908 handheld mass spectrometer, which is used to detect and identify chemical threats, explosives, narcotics and other hazardous materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.